Skip to main content
SpringerLink
Log in

Cyclooxygenase-2 and Chronic Inflammation: Drivers of Colorectal Tumorigenesis

  • Chapter
  • First Online:
Book cover Energy Balance and Gastrointestinal Cancer

Part of the book series: Energy Balance and Cancer ((EBAC,volume 4))

Abstract

A common feature of the relationship between abnormal energy balance, altered hormonal regulation, and cancer is the presence of increased inflammation. In individuals with obesity-associated metabolic disorder, an increased inflammatory response can be identified on both systemic- and tissue-specific levels. This chapter details the relationship between cyclooxygenase-2 (COX-2), a key mediator of local inflammatory response, and the development of colorectal cancer. It also describes the modulation of COX-2 activity as a means of preventing and treating colorectal tumors. Finally, this chapter addresses new data concerning the role of COX-2 activity in obesity and metabolic syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Waddell WR, Loughry RW (1983) Sulindac for polyposis of the colon. J Surg Oncol 24(1):83–87

    PubMed  CAS  Google Scholar 

  2. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Eng J Med 328:1313–1316

    CAS  Google Scholar 

  3. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD et al (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346(14):1054–1059

    PubMed  CAS  Google Scholar 

  4. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C et al (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635–639

    PubMed  CAS  Google Scholar 

  5. Phillips RK, Wallace MH, Lynch P, Hawk E, Gordon GB, Saunders B et al (2002) A randomised, double-blind, placebo-controlled study of celecoxib, a selective cyclooxygenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50(6):857–860

    PubMed  CAS  Google Scholar 

  6. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK (1993) Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80(12):1618–1619

    PubMed  CAS  Google Scholar 

  7. Waddell WR, Ganser GF, Cerise EJ, Loughry RW (1989) Sulindac for polyposis of the colon. Am J Surg 157:175–179

    PubMed  CAS  Google Scholar 

  8. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J et al (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Eng J Med 355(9):885–895

    CAS  Google Scholar 

  9. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bressalier R et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348(10):891–899

    PubMed  CAS  Google Scholar 

  10. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B et al (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125(2):612–614

    Google Scholar 

  11. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K et al (2006) A randomized trial of celecoxib to prevent sporadic colorectal adenomas. N Engl J Med 355:873–884

    PubMed  CAS  Google Scholar 

  12. Bucher C, Jordan P, Nickeleit V, Torhorst J, Mihatsch MJ (1999) Relative risk of malignant tumors in analgesic abusers. Effects of long- term intake of aspirin. Clin Nephrol 51(2):67–72

    PubMed  CAS  Google Scholar 

  13. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA (1996) Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88(14):988–993

    PubMed  CAS  Google Scholar 

  14. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD et al (1998) Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 7(2):97–102

    PubMed  CAS  Google Scholar 

  15. Garcia-Rodriguez LA, Heuerta-Alvarez C (2001) Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 12:88–93

    PubMed  CAS  Google Scholar 

  16. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC (1994) Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121(4):241–246

    PubMed  CAS  Google Scholar 

  17. Hixson LJ, Earnest DL, Fennerty MB, Sampliner RE (1993) NSAID effect on sporadic colon polyps. Am J Gastroenterol 88(10):1652–1656

    PubMed  CAS  Google Scholar 

  18. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ (2000) Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 320(7250):1642–1646

    PubMed  CAS  Google Scholar 

  19. Thun MJ, Namboodiri MM, Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325(23):1593–1596

    PubMed  CAS  Google Scholar 

  20. Ghosh N, Chaki R, Mandal V, Mandal SC (2010) COX-2 as a target for cancer chemotherapy. Pharmacol Rep 62:233–244

    PubMed  CAS  Google Scholar 

  21. Koki AT, Leahy KM, Masferrer JL (1999) Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs 8(10):1623–1638

    PubMed  CAS  Google Scholar 

  22. Subbaramaiah K, Dannenberg AJ (2003) Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24(2):96–102

    PubMed  CAS  Google Scholar 

  23. Grosser T, Yu Y, FitzGerald GA (2010) Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med 61:17–33

    PubMed  CAS  Google Scholar 

  24. Bertagnolli MM. Eicosanoids (2006) In: Shepro D, editor. Microvascular research: biology and pathology. Elsevier, San Diego, CA, p 727

    Google Scholar 

  25. Surh I, Rundhaug J, Pavone A, Mikulec C, Abel E, Fischer SM (2011) Upregulation of the EP1 receptor for prostaglandin E2 promotes skin tumor progression. Mol Carcinog 50(6):458–468

    PubMed  CAS  Google Scholar 

  26. Balch CM, Dougherty PA, Tilden AB (1982) Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients. Ann Surg 196:645–650

    PubMed  CAS  Google Scholar 

  27. Bennett A, Tacca MD, Stamford IF, Zebro T (1977) Prostaglandins from tumour of human large bowel. Br J Cancer 6:881–884

    Google Scholar 

  28. O’Banion MK, Sadowski HB, Winn V, Young DA (1991) A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 266(34):23261–23267

    PubMed  Google Scholar 

  29. Marnett LJ, DuBois RN (2002) COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 42:55–80

    PubMed  CAS  Google Scholar 

  30. Smith WL, Garavito RM, DeWitt DL (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271(52):33157–33160

    PubMed  CAS  Google Scholar 

  31. Williams CS, DuBois RN (1996) Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 270(3 Pt 1):G393–G400

    PubMed  CAS  Google Scholar 

  32. Herschman HR (1996) Prostaglandin synthase 2. Biochim Biophys Acta 1299(1):125–140

    PubMed  Google Scholar 

  33. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ (2001) Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8(2):97–114

    PubMed  CAS  Google Scholar 

  34. Herschman HR (1999) Function and regulation of prostaglandin synthase 2. Adv Exp Med Biol 469:3–8

    PubMed  CAS  Google Scholar 

  35. Stappenbeck TS, Miyoshi H (2009) The role of stromal stem cells in tissue regeneration and wound repair. Science 324:1666–1669

    PubMed  CAS  Google Scholar 

  36. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107(4):1183–1188

    PubMed  CAS  Google Scholar 

  37. Sheehan KM, Sheahan K, O’Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ et al (1999) The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282(13):1254–1257

    PubMed  CAS  Google Scholar 

  38. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S et al (2000) Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 6(10):4064–4068

    PubMed  CAS  Google Scholar 

  39. Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama J, Osada T et al (2000) Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 83(3):324–328

    PubMed  CAS  Google Scholar 

  40. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E (1996) Suppression of intestinal polyposis in Apc delta knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803–809

    PubMed  CAS  Google Scholar 

  41. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58:362–366

    PubMed  CAS  Google Scholar 

  42. Xie W, Herschman HR (1995) v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. J Biol Chem 270(46):27622–27628

    PubMed  CAS  Google Scholar 

  43. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Increased expression of cyclooxygenase-2 in HER-2-overexpressing human breast cancer cells. NCI 7th SPORE Investigators’ Workshop, Bethesda, MD

    Google Scholar 

  44. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R (1999) Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18(2):305–314

    PubMed  CAS  Google Scholar 

  45. Chen G, Wilson R, McKillop JH, Walker JJ (1994) The role of cytokines in the production of prostacyclin and thromboxane in human mononuclear cells. Immunol Invest 23(4–5):269–279

    PubMed  CAS  Google Scholar 

  46. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB et al (1996) Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 56(19):4424–4429

    PubMed  CAS  Google Scholar 

  47. Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG (2001) Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res 61(6):2720–2726

    PubMed  CAS  Google Scholar 

  48. Bonazzi A, Mastyugin V, Mieyal PA, Dunn MW, Laniado-Schwartzman M (2000) Regulation of cyclooxygenase-2 by hypoxia and peroxisome proliferators in the corneal epithelium. J Biol Chem 275:2837–2844

    PubMed  CAS  Google Scholar 

  49. Bazan NG, Lukiw WJ (2002) Cyclooxygenase-2 and presenilin-1 gene expression induced by interleukin-1beta and amyloid beta 42 peptide is potentiated by hypoxia in primary human neural cells. J Biol Chem 277:30359–30367

    PubMed  CAS  Google Scholar 

  50. Kopan R, Ilagan MX (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137:216–233

    PubMed  CAS  Google Scholar 

  51. Xie W, Herschman HR (1996) Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum. J Biol Chem 271(49):31742–31748

    PubMed  CAS  Google Scholar 

  52. Subbaramaiah K, Chung WJ, Dannenberg AJ (1998) Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways. J Biol Chem 273(49):32943–32949

    PubMed  CAS  Google Scholar 

  53. Chen C-C, Sun Y-T, Chen J-J, Chang Y-J (2001) Tumor necrosis factor-alpha-induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and I-kappaB kinase 1/2 in human alveolar epithelial cells. Mol Pharmacol 59(3):493–500

    PubMed  CAS  Google Scholar 

  54. Cok SJ, Morrison AR (2001) The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 276(25):23179–23185

    PubMed  CAS  Google Scholar 

  55. Dixon DA, Tolley ND, King PH, Nabors LB, McIntyre TM, Zimmerman GA et al (2001) Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 108(11):1657–1665

    PubMed  CAS  Google Scholar 

  56. Strillacci A, Griffoni C, Sansone P, Paterini P, Piazzi G, Lazzarini G et al (2009) MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 315:1439–1447

    PubMed  CAS  Google Scholar 

  57. Bianchini F, Kaaks R, Vainio H (2002) Overweight, obesity, and cancer risk. Lancet Oncol 3(9):565–574

    PubMed  Google Scholar 

  58. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and morality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625–1638

    PubMed  Google Scholar 

  59. Delage B, Rullier A, Capdepont M, Rullier E, Cassand P (2007) The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers. Nutr J 6(20):1475–2891

    Google Scholar 

  60. Ghoshal S, Trivedi DB, Graf GA, Loftin CD (2011) Cyclooxygenase-2 deficiency attenuates adipose tissue differentiation and inflammation in mice. J Biol Chem 286(1):889–898

    PubMed  CAS  Google Scholar 

  61. Vegiopoulos A, Muller-Decker K, Strzoda D, Schmitt I, Chichelnitskiy E, Ostertag A et al (2010) Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes. Science 328:1158–1161

    PubMed  CAS  Google Scholar 

  62. McDougall CJ, Ngoi SS, Goldman IS, Godwin T, Felix J, DeCosse JJ et al (1990) Reduced expression of HLA class I and II antigens in colon cancer. Cancer Res 50(24):8023–8027

    PubMed  CAS  Google Scholar 

  63. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP (2002) Prostaglandins as modulators of immunity. Trands Immunol 23:144–150

    CAS  Google Scholar 

  64. Sheibanie AF, Yen JH, Kharullina T, Eming F, Zhang M, Tuma R et al (2007) The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-IL-17 axis. J Immunol 178:8138–8147

    PubMed  CAS  Google Scholar 

  65. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K et al (2009) Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 15(6):633–640

    PubMed  CAS  Google Scholar 

  66. Hixon LJ, Alaberts DX, Krutzsch M, Einsphar J, Brendel K, Gross PH et al (1994) Antiproliferative effect of nonsteroidal anti-inflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prev 3:433–438

    Google Scholar 

  67. Pai R, Nakamura T, Moon WS, Tarnawski AS (2003) Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J 17(12):1640–1647

    PubMed  CAS  Google Scholar 

  68. Pai R, Sorgehan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS (2002) Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8(3):289–293

    PubMed  CAS  Google Scholar 

  69. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS (2005) Prostaglandin E2 promotes colon cancer cell growth through a novel Gs-axin-{beta}-catenin signaling axis. Science 310:1504–1510

    PubMed  CAS  Google Scholar 

  70. Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN (2005) Prostaglandin E2 enhances intestinal adenoma growth via activation of the Tas-mitogen-activated protein kinase cascade. Cancer Res 65:1822–1829

    PubMed  CAS  Google Scholar 

  71. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B et al (2004) Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6(3):285–295

    PubMed  CAS  Google Scholar 

  72. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K (2003) Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 24:985–990

    PubMed  CAS  Google Scholar 

  73. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C et al (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256(5057):668–670

    PubMed  CAS  Google Scholar 

  74. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A et al (2006) 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 103(32):12098–12102

    PubMed  CAS  Google Scholar 

  75. Han C, Michalopolous GK, Wu T (2006) Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol 207:261–270

    PubMed  CAS  Google Scholar 

  76. Donnini S, Finetti F, Solito R, Terzuoli E, Sacchetti A, Morbidelli L et al (2007) EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. FASEB J 21:2418–2430

    PubMed  CAS  Google Scholar 

  77. Mendez M, LaPointe MC (2005) PGE2-induced hypertrophy of cardiac myocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation. Am J Physiol Heart Circ Physiol 288:H2111–H2117

    PubMed  CAS  Google Scholar 

  78. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T et al (2002) Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res 62:28–32

    PubMed  CAS  Google Scholar 

  79. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H et al (1999) Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59(20):5093–5096

    PubMed  CAS  Google Scholar 

  80. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S et al (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 7(9):1048–1051

    PubMed  CAS  Google Scholar 

  81. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q et al (2006) CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 203(4):941–951

    PubMed  CAS  Google Scholar 

  82. Form DM, Auerbach R (1983) PGE2 and angiogenesis. Proc Soc Exp Biol Med 172:214–218

    PubMed  CAS  Google Scholar 

  83. Gately S, Kerbel R (2003) Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 37:179–192

    PubMed  CAS  Google Scholar 

  84. Amano H, Hayashi I, Endo H et al (2003) Host prostaglandin E(2)-EP3 signaling regulates tumor-associated antiogenesis and tumor growth. J Exp Med 197:221–232

    PubMed  CAS  Google Scholar 

  85. Niho N, Mutoh M, Kitamura T et al (2005) Suppression of azoxy-methane-induced colon cancer development in rats by a prostaglandin E receptor EP1-selective antagonist. Cancer Sci 96:260–264

    PubMed  CAS  Google Scholar 

  86. Kawamori T, Kitamura T, Wantanabe K et al (2005) Prostaglandin E receptor subtype EP(1) deficiency inhibits colon cancer development. Carcinogenesis 26:353–357

    PubMed  CAS  Google Scholar 

  87. Davids JS, Carothers AM, Damas BC, Bertagnolli MM (2010) Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis. Cancer Prev Res 3(3):348–358

    CAS  Google Scholar 

  88. Powell DW, Adegboyege PA, Di Mari JF, Mifflin RC (2005) Epithelial cells and their neighbors. I. Role of intestinal myofibroblasts in development, repair, and cancer. Am J Physiol 289:G2–G7

    CAS  Google Scholar 

  89. Otte JM, Rosenberg IM, Podolsky DK (2003) Intestinal myofibroblasts in innate immune responses. Gastroenterology 124:1866–1878

    PubMed  CAS  Google Scholar 

  90. Enders G (2007) Cyclooxygenase 2 overexpression abrogates the antiproliferative effects of TGF-beta. Br J Cancer 7:1388–1392

    Google Scholar 

  91. Buchanan FG, Wang D, Bargiacchi F et al (2003) Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278:35451–35457

    PubMed  CAS  Google Scholar 

  92. Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83(3):493–501

    PubMed  CAS  Google Scholar 

  93. Katajisto P, Vaahtomeri K, Ekman N, Ristimäki A, Bardeesy N, Feil R et al (2008) LKB1 signaling in mesenchymal cells is required for suppression of gastrointestinal polyposis. Nat Genet 40:455–459

    PubMed  CAS  Google Scholar 

  94. Rakoff-Nahoum S, Medzhitov R (2007) Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317:124–127

    PubMed  CAS  Google Scholar 

  95. Yan M, Rerko RM, Paltzer P, Markowitz SD (2004) 15-hydorxyprostaglandin dehydrogenase, a Cox-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA 101:17468–17473

    PubMed  CAS  Google Scholar 

  96. Carothers AM, Davids JS, Damas BC, Bertagnolli MM (2010) Persistent cyclooxygenase-2 inhibition downregulates NF-kB, resulting in chronic intestinal inflammation in the Min/+ mouse model of colon tumorigenesis. Cancer Res 70(11):4433–4442

    PubMed  CAS  Google Scholar 

  97. Greten FR, Arkan MC, Bollrath J, Hsu L-C, Goode J, Miething C et al (2007) NF-κB is a negative regulator of IL-1β secretion as revealed by genetic and pharmacological inhibition of IKKβ. Cell 130:918–931

    PubMed  CAS  Google Scholar 

  98. Rouzer CA, Marnett LJ (2009) Cyclooxygenases: structural and functional insights. J Lipid Res 50 Suppl:S29–S34

    PubMed  Google Scholar 

  99. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071–1080

    PubMed  CAS  Google Scholar 

  100. Hawkey CJ, Hawkey GM, Everitt S, Skelly MM, Stack WA, Gray D (2006) Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. Br J Clin Pharmacol 61(6):730–737

    PubMed  CAS  Google Scholar 

  101. Weir MR, Sperling RS, Reicin A, Gertz BJ (2003) Selective Cox-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 146:591–604

    PubMed  CAS  Google Scholar 

  102. Kang DW, Choi KY, Min DS (2011) Phospholipase D meets wnt signaling: a new target for cancer therapy. Cancer Res 71(2):293–297

    PubMed  CAS  Google Scholar 

  103. Barker N et al (2009) Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457:608–611

    PubMed  CAS  Google Scholar 

  104. Sangiorgi E, Capecchi MR (2008) Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet 40:915–920

    PubMed  CAS  Google Scholar 

  105. Li L, Clevers H (2010) Coexistence of quiescent and active adult stem cells in mammals. Science 327:542–545

    PubMed  CAS  Google Scholar 

  106. Hara A, Yoshimi N, Niwa M, Ino N, Mori H (1997) Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn J Cancer Res 88(6):600–604

    PubMed  CAS  Google Scholar 

  107. Martin S, Phillips DC, Szekely-Szucs K, Elghazi L, Desmots F, Houghton JA (2005) Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae. Cancer Res 65(24):11447–11458

    PubMed  CAS  Google Scholar 

  108. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B (2000) Role of BAX in apoptotic response to anticancer agents. Science 290:989–992

    PubMed  CAS  Google Scholar 

  109. Qui W, Wang X, Leibowitz B, Liu H, Barker N, Okada H et al (2010) Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis. Proc Natl Acad Sci USA 107(46):20027–20032

    Google Scholar 

  110. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A et al (2001) Up-regulation of cyclooxygenase-2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 121(6):1339–1347

    PubMed  CAS  Google Scholar 

  111. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN (2000) Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105(11):1589–1594

    PubMed  CAS  Google Scholar 

  112. Dormond O, Foletti A, Paroz C, Ruegg C (2001) NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 7(9):1041–1047

    PubMed  CAS  Google Scholar 

  113. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM et al (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60(5):1306–1311

    PubMed  CAS  Google Scholar 

  114. Shao J, Lee SB, Guo H et al (2003) Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 63:5218–5223

    PubMed  CAS  Google Scholar 

  115. Moran AE, Hunt DH, Javid SH, Redston M, Carothers AM, Bertagnolli MM (2004) Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem 279(41):43261–43272

    PubMed  CAS  Google Scholar 

  116. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275(15):11397–11403

    PubMed  CAS  Google Scholar 

  117. Carothers AM, Javid SH, Moran AE, Hunt DM, Redston M, Bertagnolli MM (2006) Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility. Exp Cell Res 312:387–400

    PubMed  CAS  Google Scholar 

  118. Sertznig P, Seifert M, Tilgen W, Reichrath J (2007) Prevent concepts and future outlook: function of perixosome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol 212:1–12

    PubMed  CAS  Google Scholar 

  119. He TC, Chan TA, Vogelstein B, Kinzler KW (1999) PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99(3):335–345

    PubMed  CAS  Google Scholar 

  120. Goppelt-Struebe M (1997) Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids. Biochem Pharmacol 53(10):1389–1395

    PubMed  CAS  Google Scholar 

  121. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB (1999) Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274(38):27307–27314

    PubMed  CAS  Google Scholar 

  122. Kune GA, Kune S, Watson LF (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48(15):4399–4404

    PubMed  CAS  Google Scholar 

  123. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53(6):1322–1327

    PubMed  CAS  Google Scholar 

  124. Yao R, Rioux N, Castonguay A, You M (2000) Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs’ chemopreventive efficacies in mouse lung tumorigenesis. Exp Lung Res 26(8):731–742

    PubMed  Google Scholar 

  125. Rothwell PA, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP et al (2011) Long-term effect of aspirin on colorectal cancer incidence and mortality: 2-year follow-up of five randomized trials. Lancet 376:1741–1750

    Google Scholar 

  126. Johnson CC, Hayes RB, Schoen RE, Gunter MJ, Huang WY (2010) Non-steroidal anti-inflammatory drug use and colorectal polyps in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Gastroenterol 105:2646–2655

    PubMed  CAS  Google Scholar 

  127. van Stolk R, Stoner G, Hayton WL, Chan K, DeYoung B, Kresty L et al (2000) Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 6(1):78–89

    PubMed  Google Scholar 

  128. Hirota C, Iida M, Aoyagi K, Matsumoto T, Tada S, Yao T et al (1996) Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis. Cancer 78(8):1660–1665

    PubMed  CAS  Google Scholar 

  129. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342(26):1946–1952

    PubMed  CAS  Google Scholar 

  130. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348(10):1939

    Google Scholar 

  131. Benamouzig R, Deyra J, Martin A, Mejou B, Raynaud J-J, Girard B, et al (2006) Daily soluble aspirin and prevention of colorectal adenoma recurrence: four years results of the APACC trial. American Gastroenterological Society Annual Meeting Abstracts. Gastroenterology 130(A101):869

    Google Scholar 

  132. Logan RE, Muir KR, Grainge MJ, Armitage NC, Shepherd VC, Group UT (2006) Aspirin for the prevention of recurrent colorectal adenomas – results of the UKCAP trial. American Gastroenterological Society Meeting Abstracts. Gastroenterology 130(A64):438

    Google Scholar 

  133. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092–1102

    PubMed  CAS  Google Scholar 

  134. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A et al (2006) A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131(6):1674–1682

    PubMed  CAS  Google Scholar 

  135. Chan AT, Ogino S, Fuchs CS (2009) Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302:649–658

    PubMed  CAS  Google Scholar 

  136. Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Eng J Med 356:2131–2142

    CAS  Google Scholar 

  137. Teicher BA, Korbut TT, Meon K et al (1994) Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemother Pharmacol 33:515–522

    PubMed  CAS  Google Scholar 

  138. Pyo H, Choy H, Amorino GP et al (2001) A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 7:2998–3005

    PubMed  CAS  Google Scholar 

  139. Kishi K, Petersen S, Petersen C et al (2000) Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 60:1326–1331

    PubMed  CAS  Google Scholar 

  140. Ferrandina G, Lauriola D, DiStefano MG (2002) Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 20:973–981

    PubMed  CAS  Google Scholar 

  141. Altorki NK, Port JL, Zhang F, Golijanin D, Thaler HT, Duffield-Lillico AJ et al (2005) Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res 11:114191–114197

    Google Scholar 

  142. Ferrandina G, Lauriola L, Zannoni GF et al (2002) Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13:1205–1211

    PubMed  CAS  Google Scholar 

  143. Uchida K, Schneider S, Yochim JM, Kuramochi H, Hayashi K, Takasaki K et al (2005) Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 11(9):3363–3368

    PubMed  CAS  Google Scholar 

  144. Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S et al (2008) Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib  +  chemotherapy – Cancer and Leukemia Group B Trial 30203. J Clin Oncol 26(6):848–855

    PubMed  CAS  Google Scholar 

  145. Ratnasinghe D, Daschner PJ, Anver MR et al (2001) Cyclooxygenase-2 P-glycoprotein-170 and drug resistance: is chemoprevention against multidrug resistance possible? Anticancer Res 21:2141–2147

    PubMed  CAS  Google Scholar 

  146. Raspollini MR, Amunni G, Villanucci A, Boddi V, Taddei GL (2006) Cox-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer. Acta Obstet Gynecol Scand 85(4):493–498

    PubMed  CAS  Google Scholar 

  147. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ (2000) Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 and p38 mitogen-activated protein kinase pathways. J Biol Chem 275:14838–14845

    PubMed  CAS  Google Scholar 

  148. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaninger G et al (1994) Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54(21):5602–5606

    PubMed  CAS  Google Scholar 

  149. Altorki NK, Keresztes RS, Port JL et al (2003) Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early-stage non-small cell lung cancer. J Clin Oncol 21:2645–2650

    PubMed  CAS  Google Scholar 

  150. Chow LW, Loo WT, Wai CC, Lui EL, Zhu L, Toi M (2005) Study of Cox-2, Ki67, and p53 expression to predict effectiveness of 5-fluorouracil, epirubicin and cyclophosphamide with celecoxib in treatment of breast cancer patients. Biomed Pharmacother 59(Suppl 2):S298–S301

    PubMed  CAS  Google Scholar 

  151. Chow LW, Wong JL, Toi ML (2003) Celecoxib anti-aromatase neoadjuvant trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol 86:443–447

    PubMed  CAS  Google Scholar 

  152. Milella M, Gelibter A, DiCosimo S, Bria E, Ruggieri EM, Carlini P et al (2004) Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 101(1):133–138

    PubMed  CAS  Google Scholar 

  153. Govindan R, McLeod H, Mantravadi P, Fineberg N, Helft P, Kesler K et al (2004) Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology 14(Suppl 14):18–21

    Google Scholar 

  154. Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D et al (2006) Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 91(6):2201–2204

    PubMed  CAS  Google Scholar 

  155. Prince HM, Mileshkin L, Roberts A, Ganju V, Underhill C, Catalano J et al (2005) A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clin Cancer Res 11(15):5504–5514

    PubMed  CAS  Google Scholar 

  156. Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M et al (2005) Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103(2):329–338

    PubMed  CAS  Google Scholar 

  157. Csiki I, Dang T, Gonzalez A, Gautam S, Sandler A, Campbell N et al (2002) Cyclooxygenase-2 inhibition  +  docetaxel in recurrent non-small cell lung cancer: preliminary results of a phase II trial (THO-0054). Proc Am Soc Clin Oncol 21:1187

    Google Scholar 

  158. Pan CX, Loehrer P, Seitz D, Helft P, Juliar B, Ansari R et al (2005) A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. Oncology 69(1):63–70

    PubMed  CAS  Google Scholar 

  159. Gasparini G, Gattuso D, Morabito A, Longo R, Torino F, Sarmiento R et al (2005) Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective Cox-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. Oncologist 10:710–717

    PubMed  CAS  Google Scholar 

  160. Zhang L, Ren X, Alt E, Huang S, Xu Z, Lynch PM et al (2010) Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature 464(7291):1058–1061

    PubMed  CAS  Google Scholar 

  161. Toyokuni T, Kumar JS, Walsh JC, Shapiro A, Talley JJ, Phelps ME et al (2005) Synthesis of 4-(5-[18F]fluoromethyl-3-phenylisoxazol-4-yl) benzene-sulfonamide, a new [18F]fluorinated analogue of valdecoxib, as a potential radiotracer for imaging cyclooxygenase-2 with positron emission tomography. Bioorg Med Chem Lett 15:4699–4702

    PubMed  CAS  Google Scholar 

  162. Schuller HM, Kabalka G, Smith G, Mereddy A, Akula M, Cekanova M (2006) Detection of overexpressed COX-2 in precancerous lesions of hamster pancreas and lungs by molecular imaging: implications for early diagnosis and prevention. Chem Med Chem 1:603–610

    PubMed  CAS  Google Scholar 

  163. de Vries EF, Doorduin J, Dierckx RA, van Waarde A (2008) Evaluation of [(11)C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. Nucl Med Biol 35:35–42

    PubMed  Google Scholar 

  164. Wuest F, Kniess T, Bergmann R, Pietzsch J (2008) Synthesis and evaluation in vitro and in vivo of a 11C-labeled cyclooxygenase-2 (COX-2) inhibitor. Bioorg Med Chem 16:7662–7670

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Dana Farber Cancer Institute, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Monica M. Bertagnolli M.D.

Authors
  1. Monica M. Bertagnolli M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monica M. Bertagnolli M.D. .

Editor information

Editors and Affiliations

  1. , Molecular Biology and Microbiology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, 44106, Ohio, USA

    Sanford D. Markowitz

  2. School of Medicine, Center for Science, Health & Society, Case Western Reserve University, Euclid Ave. 10900, Cleveland, 44106, Ohio, USA

    Nathan A. Berger

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Bertagnolli, M.M. (2012). Cyclooxygenase-2 and Chronic Inflammation: Drivers of Colorectal Tumorigenesis. In: Markowitz, S., Berger, N. (eds) Energy Balance and Gastrointestinal Cancer. Energy Balance and Cancer, vol 4. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-2367-6_10

Download citation

Publish with us

Policies and ethics

Search

Navigation